We therefore aimed to validate the ability of 89Zr-onartuzumab PET to assess c-MET upregulation-mediated erlotinib resistance, as well as c-MET downregulation after HSP90 inhibitor NVP-AUY-922 treatment in human NSCLC xenografts. The gene discussed is MET; the disease is non-small cell lung carcinoma.